The microbiome-gut-brain axis represents a critical bidirectional communication network linking the intestinal microbiota with the central nervous system. This pathway plays a significant role in neurodegeneration through multiple mechanisms including neural, endocrine, immune, and metabolic pathways. [1]
| Molecule | Function | Disease Association |
|---|---|---|
| SCFAs | Short-chain fatty acids - butyrate, propionate, acetate | Anti-inflammatory, barrier protection [2][3] |
| LPS | Lipopolysaccharide - endotoxin from Gram-negative bacteria | Neuroinflammation, BBB disruption [4] |
| Bile Acids | Primary/secondary bile acids via FXR/TGR5 | Neuroprotection, dopamine modulation [5] |
| Tryptophan Metabolites | Serotonin, kynurenine, indoles | Mood, neurotoxicity [6] |
| Vagus Nerve | Neural gut-brain communication | α-Syn propagation in PD |
| GABA | γ-Aminobutyric acid production | Anxiety, sedation |
| Cytokines | IL-6, TNF-α, IL-1β | Systemic inflammation |
Gut bacteria influence Aβ aggregation through:
Dysbiosis (microbial imbalance) increases:
Vagus nerve as highway: α-Syn can travel from gut to brain via:
| Strain | Mechanism | Clinical Status |
|---|---|---|
| Lactobacillus | GABA production, anti-inflammatory | Phase II trials in PD |
| Bifidobacterium | Butyrate production, barrier protection | Phase II trials in AD |
| Faecalibacterium | Anti-inflammatory SCFA | Preclinical |
| Biomarker | Source | Disease | Utility |
|---|---|---|---|
| SCFA levels | Stool, plasma | AD, PD | Therapeutic monitoring |
| LPS | Plasma, CSF | AD, PD | Inflammation marker |
| Bile acids | Plasma, stool | PD | Dopaminergic function |
| Tryptophan metabolites | Plasma, urine | AD, PD | Neurotoxicity |
| Microbiome diversity | Stool | All | Diagnostic |
Microbiome dysbiosis → increased systemic inflammation → microglial activation
The study of Microbiome Gut Brain Axis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent publications advancing our understanding of this mechanism:
Emerging research connects gut microbiome dysbiosis to corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both 4R-tauopathies characterized by tau protein aggregation in neurons and glia.
| Mechanism | Effect on Tauopathy | Evidence Status |
|---|---|---|
| SCFA deficiency | Reduced anti-inflammatory protection | Moderate |
| LPS-induced inflammation | Enhanced tau phosphorylation | Emerging |
| TMAO elevation | Pro-atherogenic, BBB dysfunction | Emerging |
| Gut barrier dysfunction | Systemic inflammation → CNS | Moderate |
| Vagal signaling | Potential protein propagation | Hypothetical |
| Parameter | CBS/PSP Finding | PD Comparison |
|---|---|---|
| Alpha diversity | Reduced | Significantly reduced |
| Firmicutes/Bacteroidetes | Altered | Often increased |
| Prevotella | May be reduced | Consistently reduced |
| Bifidobacterium | May be decreased | Reduced |
| Enterobacteriaceae | May be increased | Increased |
SCFA-Targeting Strategies:
Gut Barrier Protection:
See Section 101: Microbiome-Gut-Brain Axis CBS/PSP and Section 123: Interventions for detailed therapeutic protocols.
Recent advances in microbiome sequencing enable personalized therapeutic approaches:
| Approach | Clinical Status | Utility |
|---|---|---|
| Microbiome sequencing | Available | Patient stratification |
| Metabolomics panels | Research | Therapy guidance |
| Strain-specific probiotics | Emerging | Targeted intervention |
| FMT personalization | Investigational | Individualized reconstitution |
Kelly D, Keane J, O'Connor PM, et al. Targeting the gut-brain axis for neuropsychiatric disorders. J Neurochem. 2019. ↩︎
Sampson TR, Challis C, Jain N, et al. Gut-derived metabolites influence microglial activation and behavior. Neuron. 2020. ↩︎ ↩︎
Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019. ↩︎ ↩︎
Chen Y, Duan Y, Liu Q, et al. Gut microbiota and Alzheimer's disease: pathophysiology and therapeutic strategies. Front Cell Neurosci. 2022. ↩︎ ↩︎
Dodiya HB, Kuntz T, Shaik SM, et al. Gut microbiota-induced blood-brain barrier disruption in aging. J Exp Med. 2019. ↩︎ ↩︎
Matheoud D, Cannon T, Voisin C, et al. Intestinal infection mimics Parkinson's disease. Nat Neurosci. 2019. ↩︎